Format

Send to

Choose Destination
See comment in PubMed Commons below
Exp Neurol. 2004 Jun;187(2):455-9.

Neuroprotective effect of rasagiline in a rodent model of Parkinson's disease.

Author information

1
Laboratory of Functional Neurochemistry, Neurological Institute C. Mondino, 27100, Pavia, Italy. fabio.blandini@mondino.it

Abstract

Sprague-Dawley rats received a unilateral injection of 6-hydroxydopamine (6-OHDA) into the striatum and were treated daily for 6 weeks with increasing doses of monoamine oxidase type B inhibitor rasagiline [R(+)-N-propargyl-1-aminoindane] or saline (controls). Both doses of rasagiline markedly increased the survival of dopaminergic neurons in the lesioned substantia nigra, compared to controls (+97% and +119%, respectively). Treatment with the lower dose of rasagiline also abolished the motor stereotypies associated with nigrostriatal lesion. Our study supports the neuroprotective potential of chronic rasagiline administration in an experimental model of Parkinson's disease (PD).

PMID:
15144871
DOI:
10.1016/j.expneurol.2004.03.005
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science
    Loading ...
    Support Center